IL15 and hematologic disorder: A phase I first-in-human study of ALT-803, an IL-15 superagonist complex, was carried out in patients with hematologic malignancies who relapsed after allogeneic HSCT, resulting in an ORR of 19% with 1 CR lasting 7 months [119].